Latest Lipoproteins Stories
RVX-208 the first selective bromodomain extra-terminal (BET) protein inhibitor being developed for patients with high residual risks of cardiovascular disease SAN DIEGO,
Analysis From Prespecified Exploratory Endpoints Presented in Late-Breaking Session at ACC.15 Showed Repatha Plus Standard of Care Lowered Cardiovascular Events THOUSAND OAKS, Calif., March
Data From PCSK9 Inhibitor Study Support Regulatory Filing in Japan THOUSAND OAKS, Calif., March 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase
Data Evaluating the Effect of Repatha(TM)(Evolocumab) on LDL-C and Cardiovascular Events to be Featured in Late-Breaking Session THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
Congressional briefing highlights results of national patient research indicating the need to improve medication adherence, access to medication and enrollment of women in clinical trials, policy recommendations
Proper cholesterol management can make the difference between a full active lifestyle and one plagued with avoidable health problems.
View the Interactive Maps on www.CholesterolCounts.com for a Snapshot of Cholesterol Awareness Across the U.S. BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb.
Pantesin® Pantethine Heart Health Supplement May Maintain CoQ10 Levels* New York, NY (PRWEB) February 10, 2015 The human body needs Coenzyme Q10
WOODBRIDGE, ON, Feb. 10, 2015 /PRNewswire/ - Pivotal Therapeutics Inc.
- Growing in low tufty patches.